Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
KCNK13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNK13 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNK13 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNK12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNK12 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNK12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ9 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ6 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ6 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ15 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
KCNJ2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
KCNJ2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of KCNJ2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →